Physician profile
Leo Kusuda
NPI 1578533303
$729.96
in general payments reported to CMS, 2019-2025
19 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $37.45 · 2021: $30.86 · 2022: $134 · 2023: $176 · 2024: $88.00 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.95 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $96.48 | 2019-2023 | Myrbetriq |
| Teleflex LLC | $75.35 | 2022-2024 | Urolift |
| Tolmar, INC. | $68.20 | 2023-2025 | Eligard, Jatenzo |
| Boston Scientific Corporation | $68.05 | 2019-2024 | Spaceoar Vue System - 10ml, Rezum Generator |
| Abbvie INC. | $58.71 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $55.31 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $49.06 | 2019-2025 | |
| Urogen Pharma, INC. | $43.15 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Rochester Medical Corporation | $28.66 | 2019 | |
| Myriad Genetic Laboratories, INC. | $26.67 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $20.57 | 2023 | Seglentis |
| Progenics Pharmaceuticals, INC. | $19.47 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $17.70 | 2020 | |
| Coloplast Corp | $17.49 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $16.74 | 2019 | |
| Laborie Medical Technologies Corp. | $15.25 | 2025 | Optilume Urethral Drug Coated Balloon |
| Pfizer INC. | $13.86 | 2021 | |
| Travere Therapeutics, INC. | $4.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Kusuda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.